Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

[1]  O. Blixt,et al.  Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approach , 2018, PLoS neglected tropical diseases.

[2]  H. Feldmann,et al.  A cynomolgus macaque model for Crimean–Congo haemorrhagic fever , 2018, Nature Microbiology.

[3]  R. Hewson,et al.  Development of vaccines against Crimean-Congo haemorrhagic fever virus , 2017, Vaccine.

[4]  S. Nichol,et al.  Identification of broadly neutralizing monoclonal antibodies against Crimean‐Congo hemorrhagic fever virus , 2017, Antiviral research.

[5]  J. Koehler,et al.  A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models , 2017, PLoS neglected tropical diseases.

[6]  T. Monath,et al.  Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. , 2017, Vaccine.

[7]  P. Nuttall,et al.  The role of ticks in the maintenance and transmission of Crimean‐Congo hemorrhagic fever virus: A review of published field and laboratory studies , 2017, Antiviral research.

[8]  R. Das,et al.  Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults , 2017, The Journal of infectious diseases.

[9]  J. Keck,et al.  Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection , 2017, The Journal of infectious diseases.

[10]  F. Weber,et al.  Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice , 2017, Journal of Virology.

[11]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.

[12]  T. Edwards,et al.  Heat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication Cycle , 2016, Journal of Virology.

[13]  M. Shimojima,et al.  Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system , 2016, Archives of Virology.

[14]  B. Bosch,et al.  Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice. , 2015, Vector borne and zoonotic diseases.

[15]  H. Feldmann,et al.  Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines. , 2015, The Journal of infectious diseases.

[16]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[17]  R. Hewson,et al.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease , 2015, Human vaccines & immunotherapeutics.

[18]  J. Fuchs,et al.  First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090) , 2015, Open forum infectious diseases.

[19]  J. Eldridge,et al.  Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus , 2015, Nature.

[20]  F. Weber,et al.  A Virus-Like Particle System Identifies the Endonuclease Domain of Crimean-Congo Hemorrhagic Fever Virus , 2015, Journal of Virology.

[21]  A. Ozdarendeli,et al.  Immunization of Knock-Out α/β Interferon Receptor Mice against High Lethal Dose of Crimean-Congo Hemorrhagic Fever Virus with a Cell Culture Based Vaccine , 2015, PLoS neglected tropical diseases.

[22]  J. Pawęska,et al.  Identification of human linear B-cell epitope sites on the envelope glycoproteins of Crimean-Congo haemorrhagic fever virus , 2014, Epidemiology and Infection.

[23]  R. Davey,et al.  Crimean-Congo Hemorrhagic Fever Virus Entry into Host Cells Occurs through the Multivesicular Body and Requires ESCRT Regulators , 2014, PLoS pathogens.

[24]  H. Feldmann,et al.  Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates , 2014, PloS one.

[25]  R. Hewson,et al.  A Novel Vaccine against Crimean-Congo Haemorrhagic Fever Protects 100% of Animals against Lethal Challenge in a Mouse Model , 2014, PloS one.

[26]  M. Whitt,et al.  Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease , 2013, Virology Journal.

[27]  M. Bray,et al.  Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. , 2013, Antiviral research.

[28]  H. Ebihara,et al.  Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. , 2013, The Journal of infectious diseases.

[29]  O. Ergonul.  Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. , 2012, Current opinion in virology.

[30]  H. Ebihara,et al.  Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus , 2011 .

[31]  S. Zakeri,et al.  Mice Orally Immunized with a Transgenic Plant Expressing the Glycoprotein of Crimean-Congo Hemorrhagic Fever Virus , 2011, Clinical and Vaccine Immunology.

[32]  D. Dimitrov,et al.  Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor. , 2011, Biochemical and biophysical research communications.

[33]  M. Whitt.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. , 2010, Journal of Virological Methods.

[34]  J. Alimonti,et al.  Pathogenesis and Immune Response of Crimean-Congo Hemorrhagic Fever Virus in a STAT-1 Knockout Mouse Model , 2010, Journal of Virology.

[35]  J. Klingström,et al.  Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. , 2010, The Journal of general virology.

[36]  Å. Lundkvist,et al.  Microtubule-dependent and microtubule-independent steps in Crimean-Congo hemorrhagic fever virus replication cycle. , 2009, Virology.

[37]  Steven J M Jones,et al.  Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.

[38]  O. Ergonul.  Treatment of Crimean-Congo hemorrhagic fever. , 2008, Antiviral research.

[39]  S. Nichol,et al.  Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Processing by the Endoprotease SKI-1/S1P Is Critical for Virus Infectivity , 2007, Journal of Virology.

[40]  R. Pettersson,et al.  The Cytoplasmic Tails of Uukuniemi Virus (Bunyaviridae) GN and GC Glycoproteins Are Important for Intracellular Targeting and the Budding of Virus-Like Particles , 2007, Journal of Virology.

[41]  R. Elliott,et al.  Role of the Cytoplasmic Tail Domains of Bunyamwera Orthobunyavirus Glycoproteins Gn and Gc in Virus Assembly and Morphogenesis , 2007, Journal of Virology.

[42]  S. Nichol,et al.  N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport. , 2007, Virology.

[43]  R. Doms,et al.  Identification of a Novel C-Terminal Cleavage of Crimean-Congo Hemorrhagic Fever Virus PreGN That Leads to Generation of an NSM Protein , 2007, Journal of Virology.

[44]  A. McElroy,et al.  Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. , 2006, Vaccine.

[45]  Ö. Ergönül.  Crimean-Congo haemorrhagic fever , 2006, The Lancet Infectious Diseases.

[46]  S. Nichol,et al.  Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Precursor Is Cleaved by Furin-Like and SKI-1 Proteases To Generate a Novel 38-Kilodalton Glycoprotein , 2006, Journal of Virology.

[47]  Claire Marie Filone,et al.  Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus. , 2005, The Journal of general virology.

[48]  T. Mizutani,et al.  Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. , 2005, The Journal of general virology.

[49]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[50]  J. Bell,et al.  Vesicular stomatitis virus: re-inventing the bullet. , 2004, Trends in molecular medicine.

[51]  M. Whitt,et al.  Identification of Two Additional Translation Products from the Matrix (M) Gene That Contribute to Vesicular Stomatitis Virus Cytopathology , 2002, Journal of Virology.

[52]  S. Nichol,et al.  Characterization of the Glycoproteins of Crimean-Congo Hemorrhagic Fever Virus , 2002, Journal of Virology.

[53]  M. Whitt,et al.  Recombinant vesicular stomatitis viruses from DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Bronson,et al.  Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system , 1991, Journal of virology.

[55]  S. Singer,et al.  Passage of an integral membrane protein, the vesicular stomatitis virus glycoprotein, through the Golgi apparatus en route to the plasma membrane. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. Feldmann,et al.  Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus , 2013, PLoS neglected tropical diseases.

[57]  R. Garry,et al.  Theoretical Biology and Medical Modelling Open Access Proteomics Computational Analyses Suggest That the Carboxyl Terminal Glycoproteins of Bunyaviruses Are Class Ii Viral Fusion Protein (beta-penetrenes) Viral Fusion Proteinsbunyavirus Envelope Glycoproteinsproteomics Computational Analysesglycopro , 2022 .